Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in MSI-Negative High TMB Solid Tumors
NCT04098068Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04098068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098068.